Skip to main content
. 2021 Oct 22;6(20):e152468. doi: 10.1172/jci.insight.152468

Figure 3. β Cell–targeted PD-1 agonist ImmTAAI molecules inhibit TCR complex signaling.

Figure 3

(A) Schematic of the ECN90 β cell line: Jurkat NFL Mel5 PD-1 reporter assay. ECN90 cells were pulsed with Melan-A activating peptide, and titrations of PD-L1 or PD-1 Ab ImmTAAI molecules, PD-L1 Fc, or PPI TCR alone added. (B–D) Either ECN90 cells were incubated for 3 hours and analyzed for PD-L1 ImmTAAI binding (n = 3 and representative of 3 independent experiments) (B), or Jurkat NFL Mel5 PD-1 cells were immediately added to test activity in the PD-1 reporter assay (n = 3 and representative of 3 independent experiments) (C and D). All data are plotted as mean ± SD. Abbreviations: IgV, Immunoglobulin-like variable domain; fl, full length